Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial
Journal of Acquired Immune Deficiency Syndromes - United States
doi 10.1097/qai.0000000000001834
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2018
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)